- Home
- EVT vs VERA Comparison
EVT vs VERA Comparison
Compare EVT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVT
- VERA
- Stock Information
- Founded
- EVT 2003
- VERA 2016
- Country
- EVT United States
- VERA United States
- Employees
- EVT N/A
- VERA N/A
- Industry
- EVT Finance Companies
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- EVT Finance
- VERA Health Care
- Exchange
- EVT Nasdaq
- VERA Nasdaq
- Market Cap
- EVT 1.7B
- VERA 1.4B
- IPO Year
- EVT N/A
- VERA 2021
- Fundamental
- Price
- EVT $24.34
- VERA $21.27
- Analyst Decision
- EVT
- VERA Buy
- Analyst Count
- EVT 0
- VERA 8
- Target Price
- EVT N/A
- VERA $64.29
- AVG Volume (30 Days)
- EVT 115.5K
- VERA 1.2M
- Earning Date
- EVT 01-01-0001
- VERA 08-05-2025
- Dividend Yield
- EVT 8.32%
- VERA N/A
- EPS Growth
- EVT N/A
- VERA N/A
- EPS
- EVT 6.63
- VERA N/A
- Revenue
- EVT $69,404,302.00
- VERA N/A
- Revenue This Year
- EVT N/A
- VERA N/A
- Revenue Next Year
- EVT N/A
- VERA N/A
- P/E Ratio
- EVT $3.55
- VERA N/A
- Revenue Growth
- EVT N/A
- VERA N/A
- 52 Week Low
- EVT $19.20
- VERA $18.53
- 52 Week High
- EVT $25.83
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- EVT 59.54
- VERA 48.60
- Support Level
- EVT $23.73
- VERA $19.07
- Resistance Level
- EVT $24.27
- VERA $22.74
- Average True Range (ATR)
- EVT 0.23
- VERA 0.97
- MACD
- EVT 0.02
- VERA 0.13
- Stochastic Oscillator
- EVT 87.95
- VERA 59.99
About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest
EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.